Sponsor:
AstraZeneca
Code:
NCT07691970
Conditions
Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
Eligibility Criteria
Sex: All
Age: 5 - 70+
Healthy Volunteers: Not accepted
Interventions
Anifrolumab
Anifrolumab
Anifrolumab
Brief summary:
Conditions
Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
Study ID
NCT07691970
Start date
Aug 31, 2026
Status verified date
Nov, 2026
Completion date
Dec 30, 2032
Anticipated
Primary completion date
Dec 30, 2032
Anticipated
Eligibility Criteria
Sex: All
Age: 5 - 70+
Healthy Volunteers: Not accepted
Enrollment
1072 participants
Anticipated
Allocation
Non randomized
Intervention Model
Single group
Primary purpose
Treatment
Arms
experimental: Anifrolumab
Interventions
Anifrolumab
Anifrolumab
Anifrolumab
Primary outcome measure
Central contacts
Locations
Research Site
Recruiting
Los Angeles, California, United States, 90045
Research Site
Recruiting
Boca Raton, Florida, United States, 33486
Research Site
Recruiting
Fort Lauderdale, Florida, United States, 33309
Research Site
Recruiting
Charlotte, North Carolina, United States, 28207
Sponsor
AstraZeneca
Last update posted
Nov 10, 2026
Last verified
Nov, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-17. This information was provided to ClinicalTrials.gov by AstraZeneca on 2026-11-10. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.